Advertisement

Tumor Biology

, Volume 34, Issue 5, pp 2759–2764 | Cite as

C282Y polymorphism in the HFE gene is associated with risk of breast cancer

  • Xiaoyan Liu
  • Chunlei Lv
  • Xiaorong Luan
  • Ming Lv
Research Article

Abstract

The C282Y and H63D polymorphisms in the HFE gene have been implicated in susceptibility of breast cancer, but a number of studies have reported inconclusive results. The aim of this study is to investigate the association between the C282Y and H63D polymorphisms in the HFE gene and breast cancer risk by meta-analysis. We searched PubMed and Embase databases, covering all related studies until March 2, 2013. Statistical analysis was performed using STATA 10.0. A total of 7 studies including 1,720 cases and 18,296 controls for HFE C282Y polymorphism and 5 studies including 942 cases and 1,571 controls for HFE H63D polymorphism were included in the meta-analysis. The results showed that HFE C282Y polymorphism was significantly associated with increased risk of breast cancer under homozygotes vs. wild-type model (OR = 2.06, 95%CI = 1.19–3.58) and recessive model (OR = 1.98, 95%CI = 1.14–3.44) but not under heterozygotes vs. wild-type model (OR = 0.97, 95%CI = 0.70–1.35), dominant model (OR = 1.00, 95%CI = 0.72–1.40) and multiplicative model (OR = 1.04, 95%CI = 0.76–1.42). However, we did not find any association between HFE H63D polymorphism and breast cancer risk under all genetic models. This current meta-analysis suggested that C282Y polymorphism rather than H63D might be associated with increased risk of breast cancer.

Keywords

HFE Polymorphism Breast cancer Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Weinberg ED. The role of iron in cancer. Eur J Cancer Pre. 1996;5:19–36.Google Scholar
  2. 2.
    Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408.CrossRefPubMedGoogle Scholar
  3. 3.
    Beckman LE, Van Landeghem GF, Sikström C, Wahlin A, Markevärn B, Hallmans G, et al. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis. 1999;20:1231–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Kallianpur AR, Hall LD, Yadav M, Byrne DW, Speroff T, Dittus RS, et al. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:1155–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Abraham BK, Justenhoven C, Pesch B, Harth V, Weirich G, Baisch C, et al. Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1102–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Kondrashova TV, Neriishi K, Ban S, Ivanova TI, Krikunova LI, Shentereva NI, et al. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim Biophys Acta. 2006;1762:59–65.CrossRefPubMedGoogle Scholar
  7. 7.
    Syrjäkoski K, Fredriksson H, Ikonen T, Kuukasjärvi T, Autio V, Matikainen MP, et al. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients. Int J Cancer. 2006;118:518–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51:1311–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Batschauer AP, Cruz NG, Oliveira VC, Coelho FF, Santos IR, Alves MT, et al. HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women. Mol Cell Biochem. 2011;357:247–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Gunel-Ozcan A, Alyilmaz-Bekmez S, Guler EN, Guc D. HFE H63D mutation frequency shows an increase in Turkish women with breast cancer. BMC Cancer. 2006;6:37.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D’Agostino Jr R, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011;71:6728–37.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  13. 13.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  14. 14.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMedGoogle Scholar
  15. 15.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Asberg A, Thorstensen K, Irgens WØ, Romundstad PR, Hveem K. Cancer risk in HFE C282Y homozygotes: results from the HUNT 2 study. Scand J Gastroenterol. 2013;48:189–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Barton JC, Bertoli LF, Acton RT. HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer. 2004;4:6.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Fargion S, Valenti L, Fracanzani AL. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology. 2010;51:1119–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res. 2010;29:18.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Agudo A, Bonet C, Sala N, Muñoz X, Aranda N, Fonseca A., et al. Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Carcinogenesis. 2013 Mar 5. doi: 10.1093/carcin/bgt045.

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Xiaoyan Liu
    • 1
  • Chunlei Lv
    • 2
  • Xiaorong Luan
    • 3
  • Ming Lv
    • 4
  1. 1.Department of Obstetrics and Gynecology, Qilu HospitalShandong UniversityJinanChina
  2. 2.Hospital Attached to Shandong University of Traditional Chinese MedicineJinanChina
  3. 3.Department of Nursing, Qilu HospitalShandong UniversityJinanChina
  4. 4.Qilu HospitalShandong UniversityJinanChina

Personalised recommendations